[Does hypothyroidism potentialize muscular toxicity of fibrates?].
作者信息
Harlé J R, Toussirot E, Disdier P, Drancourt M, Weiller P J
出版信息
Rev Med Interne. 1990 Jul-Aug;11(4):336. doi: 10.1016/s0248-8663(05)80871-9.
PMID:2096444
Abstract
摘要
相似文献
1
[Does hypothyroidism potentialize muscular toxicity of fibrates?].甲状腺功能减退会增强贝特类药物的肌肉毒性吗？
Rev Med Interne. 1990 Jul-Aug;11(4):336. doi: 10.1016/s0248-8663(05)80871-9.
2
[Does hypothyroidism predispose muscular toxicity of fibrates?].[甲状腺功能减退症是否易导致贝特类药物的肌肉毒性？]
Rev Med Interne. 1991 Mar-Apr;12(2):159. doi: 10.1016/s0248-8663(05)81387-6.
3
[Myositis, hypothyroidism and fibrates].[肌炎、甲状腺功能减退症与贝特类药物]
Rev Med Interne. 1991 Nov-Dec;12(6):475. doi: 10.1016/s0248-8663(05)83200-x.
4
Transitory deficit in high-density lipoproteins and apolipoprotein A-I.高密度脂蛋白和载脂蛋白A-I的短暂缺乏
Clin Chem. 1990 Mar;36(3):580-1.
5
Fibrate-induced increase in blood urea and creatinine.贝特类药物引起的血尿素和肌酐升高。
Nephrol Dial Transplant. 2001 Jul;16(7):1515. doi: 10.1093/ndt/16.7.1515.
6
Creatinine rise after fibrate therapy in renal graft recipients.肾移植受者接受贝特类药物治疗后肌酐升高。
Lancet. 1993 Mar 27;341(8848):840. doi: 10.1016/0140-6736(93)90625-q.
7
Fibrates and renal function.贝特类药物与肾功能
Clin Nephrol. 2003 Jul;60(1):65-6. doi: 10.5414/cnp60065.
8
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.贝特类药物对人胚胎横纹肌肉瘤细胞的细胞特异性毒性。
Naunyn Schmiedebergs Arch Pharmacol. 2003 Mar;367(3):289-96. doi: 10.1007/s00210-002-0660-9. Epub 2003 Feb 8.
9
Acute muscular syndrome after bezafibrate.苯扎贝特引起的急性肌肉综合征。
Klin Wochenschr. 1981 Dec 1;59(23):1321. doi: 10.1007/BF01711183.
10
Ciprofibrate and lipid profile.
Lancet. 1994 Oct 1;344(8927):955. doi: 10.1016/s0140-6736(94)92307-8.
引用本文的文献
1
Myxoedema revealed by simvastatin induced myopathy.辛伐他汀诱发的肌病导致的黏液性水肿
BMJ. 1994 Feb 26;308(6928):588. doi: 10.1136/bmj.308.6928.588.
Zotero 插件